Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis

ABSTRACT: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half the patient population. This study aims to identify biomarkers for early imrecoxib efficacy evaluation in OA for personalized therapy optimization. From September 2021 to January 2022, imrecoxib was administered to patients with OA at Nanjing Drum Tower Hospital. Plasma samples from these patients underwent proteomic analysis through the four-dimensional data-independent acquisition (4D-DIA) method, followed by bioinformatics analysis. Potential differentially expressed proteins (DEPs) were validated using enzyme-linked immunosorbent assay (ELISA). Sixty-six patients with knee OA were included and divided into responders (n=35) and non-responders (n=31). Proteomic analysis was conducted on 15 patients from each group, and ELISA validation was performed for every patient. We found 140 DEPs between the two groups after administering imrecoxib treatment, characterized by 29 proteins showing up-regulation and 111 displaying down-regulation (p < 0.05, fold change > ±1.2). Galectin-1 (LGALS1), galectin-3 (LGALS3), and the cluster of differentiation 44 (CD44) could be utilized to evaluate the clinical response to imrecoxib in the treatment of OA after ELISA validation.This study successfully identified biomarkers for evaluating imrecoxib's clinical response in OA patients using 4D-DIA technology. These biomarkers may play a vital role in future personalized OA treatment strategies, pending further confirmation.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

SUBMITTER: Yuan Zhang  

LAB HEAD: Weihong Ge

PROVIDER: PXD047236 | Pride | 2024-01-19

REPOSITORIES: Pride